The May reimbursement list included two highly anticipated treatments: polatuzumab vedotin and Car-T for patients with refractory and relapsed B-cell lymphoma who had no previous treatment options.
- So far, there have been no treatment options for these patients. That is why these therapies are groundbreaking - told Medexpress prof. Iwona Hus, deputy head of the Hematology Clinic of the Institute of Hematology and Transfusion Medicine in Warsaw, president of the Polish Society of Hematology and Transfusion Medicine.
Expected decision
Until a few years ago, medicine did not have much to offer a group of patients with refractory and relapsed B-cell lymphoma who were not eligible for autologous transplant. In 2020, polatuzumab vedotin was registered in the EU, a year later the t...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
